Assessment of performance of survival prediction models for cancer prognosis

BMC Medical Research Methodology

Volumn 12, Issue , 2012, Pages

  Chen, Hung Chia ^a   Kodell, Ralph L ^b   Cheng, Kuang Fu ^c   Chen, James J ^a,c  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

AREA UNDER THE CURVE; ARTICLE; BREAST TUMOR; COMPARATIVE STUDY; COMPUTER SIMULATION; DISEASE FREE SURVIVAL; FEMALE; HUMAN; MORTALITY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RECEIVER OPERATING CHARACTERISTIC; STATISTICAL MODEL; SUPPORT VECTOR MACHINE; SURVIVAL;

AREA UNDER CURVE; BREAST NEOPLASMS; COMPUTER SIMULATION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LOGISTIC MODELS; MODELS, STATISTICAL; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; ROC CURVE; SUPPORT VECTOR MACHINES; SURVIVAL ANALYSIS;

EID: 84864772523     PISSN: None     EISSN: 14712288     Source Type: Journal    
DOI: 10.1186/1471-2288-12-102     Document Type: Review

References (54)

1. Cox DR, Oakes D, Analysis of survival data Chapman and Hall, London 1984
2. Thin primary cutaneous malignant melanoma: a prognostic tree for 10-year metastasis is more accurate than American Joint Committee on Cancer staging. Gimotty PA, Guerry D, Ming ME, et al. J Clin Oncol 2004 22 3668 3676 10.1200/JCO.2004.12.015 15302909 (Pubitemid 41095205)
3. Improved prediction of recurrence after curative resection of colon carcinoma using tree-based risk stratification. Radespiel-Troger M, Hohenberger W, Reingruber B, Cancer 2004 100 958 967 10.1002/cncr.20065 14983491 (Pubitemid 38222856)
4. Classification of localized melanoma by the exponential survival trees method. Huang X, Soong SJ, McCarthy WH, Urist MM, Balch CM, Cancer 1997 79 1122 1128 10.1002/(SICI)1097-0142(19970315)79:6<1122::AID-CNCR10>3.0.CO;2-1 9070489 (Pubitemid 27118209)
5. Recursive partitioning for prognostic grouping of patients with clinically localized prostate carcinoma. Banerjee M, Biswas D, Sakr W, Wood DP, Cancer 2000 89 404 411 10.1002/1097-0142(20000715)89:2<404::AID-CNCR28>3. 0.CO;2-M 10918173 (Pubitemid 30489891)
6. A comparison of estimated proportional hazards models and regression trees. Segal MR, Bloch DA, Stat Med 1989 8 539 550 10.1002/sim.4780080503 2727474 (Pubitemid 19116000)
7. Features of tree-structured survival analysis. Segal MR, Epidemiology 1997 8 344 346 9209845
8. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Alizadeh AA, Elsen MB, Davis RE, et al. Nature 2000 403 503 511 10.1038/35000501 10676951 (Pubitemid 30082188)
9. Association of GUCY2C expression in lymph nodes with time to recurrence and disease-free survival in pN0 colorectal cancer. Waldman SA, Hyslop T, Schulz S, et al. JAMA 2009 301 745 752 10.1001/jama.2009.141 19224751
10. Translation of microarray data into clinically relevant cancer diagnostic tests using gene expression ratios in lung cancer and mesothelioma. Gordon GJ, Jensen RV, Hsiao LL, et al. Cancer Res 2002 62 4963 4967 12208747 (Pubitemid 34984420)
11. Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Shedden K, Taylor JM, Enkemann SA, et al. Nat Med 2008 14 822 827 10.1038/nm.1790 18641660
12. Combining Gene Expression Profiles and Clinical Parameters for Risk Stratification in Medulloblastomas. Fernandez-Teijeiro A, Betensky RA, Sturla LM, Kim JYH, Tamayo P, Pomeroy SL, J Clin Oncol 2004 22 994 998 10.1200/JCO.2004.03.036 14970184 (Pubitemid 41095030)
13. Host immune gene polymorphisms in combination with clinical and demographic factors predict late survival in diffuse large B-cell lymphoma patients in the pre-rituximab era. Habermann TM, Wang SS, Maurer MJ, et al. Blood 2008 112 2694 2702 10.1182/blood-2007-09-111658 18633131
14. Using cross-validation to evaluate predictive accuracy of survival risk classifiers based on high-dimensional data. Briefings in Bioinformatics. Simon RM, Subramanian J, Li MC, Menezes S, Brief Bioinform 2011 12 203 214 10.1093/bib/bbr001 21324971
15. Semi-supervised methods to predict patient survival from gene expression data. Bair E, Tibshirani R, PLoS Biol 2004 2 0511 0514
16. Interpretation of Genomic Data: Questions and Answers. Simon RM, Semin Hematol 2008 45 196 204 10.1053/j.seminhematol.2008.04.008 18582627 (Pubitemid 351876122)
17. Evaluating the Yield of Medical Tests. Harrell FE, Califf RM, Pryor DB, Lee KL, Rosati RA, JAMA 1982 247 2543 2546 10.1001/jama.1982.03320430047030 7069920 (Pubitemid 12155954)
18. Confidence intervals for rank statistics: Somers' D and extensions. Newson R, Stata J 2006 6 309 334 (Pubitemid 44505049)
19. Time-dependent ROC curves for censored survival data and a diagnostic marker. Heagerty PJ, Lumley T, Pepe MS, Biometrics 2000 56 337 344 10.1111/j.0006-341X.2000.00337.x 10877287 (Pubitemid 30422619)
20. Microarray gene expression data with linked survival phenotypes: diffuse large-B-cell lymphoma revisited. Segal MR, Biostatistics 2006 7 268 285 16284340
21. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. Buyse M, Loi S, vant Vee L, et al. J Natl Cancer Inst 2006 6 1183 1192 (Pubitemid 44390989)
22. Gene expression-based prognostic signatures in lung cancer ready for clinical use? Subramanian J, Simon RM, J Natl Cancer Inst 2010 102 464 474 10.1093/jnci/djq025 20233996
23. On the prognostic value of survival models with application to gene expression signatures. Hielscher T, Zucknick M, Werft W, Benner A, Stat Med 2010 30 818 829
24. Assessment of survival prediction models based on microarray data. Schumacher M, Binder H, Gerds T, Bioinformatics 2007 23 1768 1774 10.1093/bioinformatics/btm232 17485430 (Pubitemid 47250309)
25. Gene expression profiling: does it add predictive accuracy to clinical characteristics in cancer prognosis? Dunkler D, Michiels S, Schemper M, Eur J Cancer 2007 43 745 751 10.1016/j.ejca.2006.11.018 17257824 (Pubitemid 46502906)
26. Gene expression profiling predicts clinical outcome of breast cancer. van t-Veer LJ, Dai H, van de Vijver MJ, et al. Nature 2002 415 530 536 10.1038/415530a 11823860 (Pubitemid 34130608)
27. Critical review of published microarray studies for cancer outcome and guidelines on statistical analysis and reporting. Dupuy A, Simon RM, J Natl Cancer Inst 2007 99 147 157 10.1093/jnci/djk018 17227998
28. Three Immunomarker support vector machines-based prognostic classifiers for Stage IB Non-Small-Cell Lung Cancer. Zhu ZH, Sun BY, Ma Y, et al. J Clin Oncol 2009 27 1091 1099 10.1200/JCO.2008.16.6991 19188679
29. Predicting neuroendocrine tumor (carcinoid) neoplasia using gene expression profiling and supervised machine learning. Drozdov I, Kidd M, Nadler B, et al. Cancer 2009 115 1638 1650 10.1002/cncr.24180 19197975
30. An overview of techniques for linking high-dimensional molecular data to time-to-event endpoints by risk prediction models. Binder H, Porzelius C, Schumacher M, Biom J 2011 53 2 170 189 10.1002/bimj.201000152 21328602
31. Assessment and comparison of prognostic classification schemes for survival data. Graf E, Schmoor C, Sauerbrei W, Schumacher M, Stat Med 1999 18 2529 2545 10.1002/(SICI)1097-0258(19990915/30)18:17/18<2529::AID-SIM274>3. 0.CO;2-5 10474158 (Pubitemid 29423514)
32. MicroRNA signature predicts survival and relapse in lung cancer. Yu SL, Chen HY, Chang GC, et al. Cancer Cell 2008 13 48 57 10.1016/j.ccr.2007.12.008 18167339 (Pubitemid 350309743)
33. Serum MicroRNA signatures identified in a genome-wide serum MicroRNA expression profiling predict survival of non-small-cell lung cancer. Hu Z, Chen X, Zhao Y, et al. J Clin Oncol 2010 28 1721 1726 10.1200/JCO.2009.24.9342 20194856
34. Gene expression signature-based prognostic risk scores in gastric cancer. Cho JY, Lim JY, Cheong JH, et al. Clin Cancer Res 2011 17 1850 1857 10.1158/1078-0432.CCR-10-2180 21447720
35. Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the intergroupe francophone du Myelome. Decaux O, Lode L, Magrangeas F, et al. J Clin Oncol 2008 26 4798 4805 10.1200/JCO.2007.13.8545 18591550
36. Non-overlapping and non-cell-type-specific gene expression signatures predict lung cancer survival. Sun Z, Wigle DA, Yang P, J Clin Oncol 2008 26 877 883 10.1200/JCO.2007.13.1516 18281660 (Pubitemid 351398079)
37. Identification and validation of a gene expression signature that predicts outcome in adult men with germ cell tumors. Korkola JE, Houldsworth J, Feldman DR, et al. J Clin Oncol 2009 27 5240 5247 10.1200/JCO.2008.20.0386 19770384
38. The relative importance of prognostic factors in studies of survival. Schemper M, Stat Med 1993 12 2377 2382 10.1002/sim.4780122413 8134740 (Pubitemid 24007156)
39. Estimating the error rate of a prediction rule: improvement on cross validation. Efron B, J Am Stat Assoc 1983 78 316 331 10.1080/01621459.1983. 10477973
40. Improvement on cross-validation: the.632+ bootstrap method. Efron B, Tibshirani R, J Am Stat Assoc 1997 92 548 560
41. Efron B, Tibshirani R, An Introduction to the Bootstrap Chapman and Hall, New York 1998
42. Development of biomarker classifiers from high-dimensional data. Baek S, Tsai CA, Chen JJ, Brief Bioinfor 2009 10 537 546 10.1093/bib/bbp016
43. Steyerberg EW, Clinical Prediction Models, A Practical Approach to Development, Validation and Updating Springer, New York 2009 Section 19.7: 352-357
44. Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer. Smith JJ, Deane NG, Wu F, et al. Gastroenterology 2010 138 958 968 10.1053/j.gastro.2009.11.005 19914252
45. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. Loi S, Haibe-Kains B, Desmedt C, et al. J Clin Oncol 2007 25 1239 1246 10.1200/JCO.2006.07.1522 17401012 (Pubitemid 46640570)
46. An evaluation of resampling methods for assessment of survival risk prediction in high-dimensional settings. Subramanian J, Simon R, Stat Med 2011 30 642 653 10.1002/sim.4106 21337359
47. Qualitative assessment of the progesterone receptor and HER2 improves the nottingham prognostic index up to 5years after breast cancer diagnosis. van Belle V, van Calster B, Brouckaert O, et al. J Clin Oncol 2010 28 4129 4134 10.1200/JCO.2009.26.4200 20713855
48. Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Wierda WG, OBrien S, Wang X, et al. Blood 2007 109 4679 4685 10.1182/blood-2005-12-051458 17299097 (Pubitemid 46827758)
49. Postoperative Nomogram for Disease-Specific Survival After an R0 Resection for Gastric Carcinoma. Kattan MW, Karpeh MS, Mazumdar M, Brennan MF, J Clin Oncol 2003 21 3647 3650 10.1200/JCO.2003.01.240 14512396 (Pubitemid 46594058)
50. Anew prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Hoster E, Dreyling M, Klapper W, et al. Blood 2008 111 558 565 10.1182/blood-2007-06-095331 17962512
51. Three-Gene Prognostic Classifier for Early-Stage Non-Small-Cell Lung Cancer. Lau SK, Boutros PC, Pintilie M, et al. J Clin Oncol 2007 25 5562 5569 10.1200/JCO.2007.12.0352 18065728
52. Prediction of Survival following First-Line Chemotherapy in Men with Castration-Resistant Metastatic Prostate Cancer. Amstrong AJ, Garrett-Mayer E, de Wit Ronald, Tannock I, Eisenberger M, Clin Cancer Res 2010 16 203 211 10.1158/1078-0432.CCR-09-2514 20008841
53. Quantifying and comparing the accuracy of binary biomarkers when predicting a failure time outcome. Moskowitz CS, Pepe MS, Stat Med 2004 23 1555 1570 10.1002/sim.1747 15122736 (Pubitemid 38660408)
54. Prediction error estimation: a comparison of resampling methods. Molinaro AM, Simon R, Pfeiffer RM, Bioinformatics 2005 21 3301 3307 10.1093/ bioinformatics/bti499 15905277 (Pubitemid 41418445)